Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
Therapeutic potential of prolactin-releasing anti-dopaminergic agents in experimental diabetic retinopathy model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Peker Kubra, Unsal Ayse Ipek Akyuz, Meteoglu Ibrahim, Erkan Erol, Bekmez Sinan, Eroglu Sayime Aydin, Omurlu Imran Kurt, Dost Turhan, Demirci Buket
Аннотация
KEY MESSAGES: WHAT IS KNOWN : • Anti-dopaminergic agents (metoclopramide (MCP), trimethobenzamide (TMB), and domperidone (DOM)) are used for diabetic gastroparesis, but their effects on diabetic eye are not well studied.
WHAT IS NEW: • These drugs do not affect intraocular pressure or tear production in diabetic rats. • They increase retinal prolactin receptor expression and reduce VEGF and CD31 immunoreactivity, indicating modulation of angiogenesis-related markers in the diabetic retina. • These findings may encourage future research to explore the potential role of prolactin-elevating antidopaminergic agents in diabetic retinopathy.
WHAT IS NEW: • These drugs do not affect intraocular pressure or tear production in diabetic rats. • They increase retinal prolactin receptor expression and reduce VEGF and CD31 immunoreactivity, indicating modulation of angiogenesis-related markers in the diabetic retina. • These findings may encourage future research to explore the potential role of prolactin-elevating antidopaminergic agents in diabetic retinopathy.